Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 14Thoracic 6Gynecologic 6Genitourinary 5Gastrointestinal 4Sarcoma 3Dermatologic 3Head & Neck 2Plasma cell 1Other solid neoplasm 1Endocrine 1CNS 1

Conditions

Multiple Myeloma 118Myelodysplastic Syndromes 37Hodgkin Disease 35Leukemia, Myeloid, Acute 33Lymphoma 31Lymphoma, Non-Hodgkin 30Neoplasms, Plasma Cell 28Precursor Cell Lymphoblastic Leukemia-Lymphoma 26Leukemia 26Leukemia, Lymphocytic, Chronic, B-Cell 23Leukemia, Myelogenous, Chronic, BCR-ABL Positive 22Myeloproliferative Disorders 19Hematologic Neoplasms 18Primary Myelofibrosis 17Recurrence 12Anemia, Aplastic 12Lymphoma, Follicular 11Lymphoma, Mantle-Cell 10Graft vs Host Disease 10Lymphoma, B-Cell, Marginal Zone 9Hematologic Diseases 9Burkitt Lymphoma 9Leukemia, Prolymphocytic 8Leukemia, Plasma Cell 8Leukemia, Myelomonocytic, Chronic 8Anemia, Refractory, with Excess of Blasts 6Polycythemia Vera 4Ovarian Neoplasms 4Lymphoma, B-Cell 4Waldenstrom Macroglobulinemia 3

Interventions

Cyclophosphamide 2pembrolizumab 1fludarabine 1daratumumab 1Specimen Handling 1Rituximab 1Paracentesis 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Lenalidomide 1Gemcitabine 1Doxorubicin 1Dexamethasone 1Carboplatin 1Capecitabine 1Calcium Dobesilate 1Bortezomib 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × fludarabine × Plasma cell × Clear all
NCT04025216 2024-01-24

A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers

Gilead Sciences

Phase 1 Terminated
16 enrolled
BreastGynecologicPlasma cellThoracic

Carcinoma, Non-Small-Cell Lung, Fallopian Tube Neoplasms, Multiple Myeloma, Ovarian Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡